Cytokinetics CYTK Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$829.61M-5.7% | -$784.96M-4.4% | -$751.94M-24.0% | -$606.31M+1.5% | -$615.26M-4.4% | ||
| $11.2M+10.6% | $10.13M+5.0% | $9.65M+2.9% | $9.38M-1.3% | $9.5M-0.3% | ||
| $119.13M+6.1% | $112.29M+3.9% | $108.03M+5.2% | $102.69M+2.9% | $99.78M+2.0% | ||
| $4.82M+332% | $1.11M-28.8% | $1.56M-81.4% | $8.41M+614% | $1.18M-92.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $41.76M+24.3% | $33.6M+94.1% | $17.31M+13.8% | $15.21M+182% | $5.39M-62.0% | ||
| $500K-83.0% | $2.93M-59.2% | $7.18M-20.1% | $8.98M+335% | -$3.82M-257% | ||
| -$11.83M-89.2% | -$6.25M— | —— | —— | —— | ||
| —— | —— | —— | $1.34M— | —— | ||
| -$523.85M-2.7% | -$510.01M-17.8% | -$432.93M-1.4% | -$426.92M-7.3% | -$398M-0.5% | ||
| $25.07M+1.1% | $24.81M+21.3% | $20.45M+73.3% | $11.8M+23.3% | $9.57M+145% | ||
| $1.01B-4.9% | $1.06B+26.8% | $838.65M+16.9% | $717.6M-45.2% | $1.31B+1.3% | ||
| —— | —— | —— | —— | $100.43M— | ||
| —— | —— | —— | —— | —— | ||
| —— | $729.46M+33.3% | $547.1M+50.0% | $364.73M+100% | $182.37M— | ||
| $10.86M+0.5% | $10.81M+0.5% | $10.76M+0.5% | $10.71M+0.5% | $10.66M+22.8% | ||
| $47.33M+31.5% | $35.98M+29.4% | $27.81M+2.3% | $27.2M— | —— | ||
| —— | —— | —— | $683K-25.3% | $914K-2.7% | ||
| $3.3M+33.5% | $2.47M+1.6% | $2.43M— | —— | —— | ||
| $527.47M+0.6% | $524.46M+26.0% | $416.14M+367% | $89.1M-89.3% | $831.57M-10.6% | ||
| —— | —— | —— | -$786K-793% | -$88K-142% | ||
| —— | —— | —— | —— | —— | ||
| $14.85M-35.2% | $22.91M+11.7% | $20.51M-19.1% | $25.35M-0.3% | $25.41M-2.2% | ||
| $6.1M+45.2% | $4.2M-6.7% | $4.5M0.0% | $4.5M+400% | $900K-30.8% | ||
| —— | $0+100% | -$11.25K+50.0% | -$22.5K+33.3% | -$33.75K+25.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $1.34M— | —— | ||
| -$9.74M+10.2% | -$10.84M-25.4% | -$8.64M-4.0% | -$8.31M-8.2% | -$7.68M-5.9% | ||
| -$11.83M-89.2% | -$6.25M— | —— | —— | —— | ||
| $500K-83.0% | $2.93M-59.2% | $7.18M-20.1% | $8.98M+335% | -$3.82M-257% | ||
| -$11.68M+26.9% | -$15.98M+22.5% | -$20.6M+29.0% | -$29M+13.3% | -$33.47M-2.9% | ||
| —— | —— | -$18.1M+40.7% | -$30.5M-94.3% | -$15.7M+19.9% | ||
| $63.08M+8.1% | $58.37M+4.2% | $55.99M+2.9% | $54.39M+3.1% | $52.78M+7.9% | ||
| $6M+6.3% | $5.65M+8.6% | $5.2M+7.6% | $4.83M+6.2% | $4.55M+5.4% | ||
| $27.9M+21.8% | $22.9M+27.5% | $17.96M+13.7% | $15.8M+20.3% | $13.13M+13.6% | ||
| $86K+244% | $25K-30.6% | $36K+2.9% | $35K— | —— | ||
| $1.09B-1.6% | $1.1B+4.4% | $1.06B+10.9% | $953.05M+12.8% | $844.65M+13.5% | ||
| —— | —— | —— | $683K-25.3% | $914K-2.7% | ||
| —— | $175M-3.4% | $181.25M-3.3% | $187.5M-3.2% | $193.75M-3.1% | ||
| —— | —— | —— | —— | —— | ||
| $39.67M+10.3% | $35.98M+29.4% | $27.81M+2.3% | $27.2M-12.7% | $31.14M-41.3% | ||
| —— | —— | —— | $6.11M— | —— | ||
| —— | —— | —— | —— | $3.83M+653% | ||
| -$548.92M-2.6% | -$534.82M-18.0% | -$453.38M-3.3% | -$438.72M-7.6% | -$407.57M-1.9% | ||
| -$548.92M-2.6% | -$534.82M-18.0% | -$453.38M-3.3% | -$438.72M-7.6% | -$407.57M-1.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cytokinetics generate?
- Cytokinetics (CYTK) generated -$523.8M in operating cash flow over the trailing twelve months.
- What is Cytokinetics's free cash flow?
- After $25.1M of capital expenditures, Cytokinetics's free cash flow was -$548.9M over the trailing twelve months, down 34.7% year over year.
- Where does Cytokinetics's cash flow data come from?
- Every line is extracted from Cytokinetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
